



Novo Nordisk in New Hampshire

Novo Nordisk US Bio Production, Inc., in West Lebanon, New Hampshire, expands the Novo Nordisk manufacturing capacity for biopharmaceutical products. As part of the global product supply network, overseen from our company's headquarters in Denmark, the site's purpose is to meet current and future demand for our rare disease products. Operators and technicians work various shifts around-the-clock depending on facility and production needs.

A part of the Upper Valley community since 2014, Novo Nordisk's current facilities include a footprint of 215,000 square feet on 16.2 acres. The site hosts specialized and skilled employees and is a valuable asset in the Novo Nordisk manufacturing portfolio.



Vision for the future

Currently, our focus is on the manufacturing of hemophilia and growth hormone disorder products. As part of Novo Nordisk's long-term plan, the facility in the future may produce other new biopharmaceutical ingredients from Novo Nordisk's development portfolio.

Sustainability

At Novo Nordisk, we are working to eliminate the environmental footprint from our operations and drive a circular transition across the company to achieve our zero environmental impact ambition. In 2022, this site achieved a key milestone in the Circular for Zero initiative by transferring to Renewable Natural Gas (RNG) as one of our sources of energy.

For the community

We are parents, colleagues, neighbors, and friends—people living with the complexities of serious diseases. And we believe in the combination of science and soul to bring better health outcomes to those living with rare chronic conditions. We live this mission at Novo Nordisk every day to benefit patients, their families, as well as the broader community.

Novo Nordisk has a strong tradition of generously giving of its time, talent, and financial report in the local community and is committed to making a difference in the Upper Valley through support for local organizations and by providing life-changing careers with competitive benefits to our employees.

Location established 2014



350 EMPLOYEES



SITE MILESTONES

In 2018 & 2019, the U.S. Food and Drug Administration (FDA) approved two medicines produced at the facility for the treatment of adults and children with hemophilia A.

In 2020, the FDA approved the growth hormone disorder medicine produced at the facility for the treatment of growth hormone deficiency.

In 2022 Site NH swapped from Propane to Renewable Natural Gas (RNG) and is now approximately 98% powered by renewable energy.



SITE AWARDS

Business NH Magazine

- Best Place to Work since 2016-2018;
- BPW Hall of Fame 2020-2021



215,000 square feet manufacturing facilities located on a 16-acre lot



24/7 OPERATIONS

New Hampshire Location
9 Technology Drive
West Lebanon, NH 03784

About Novo Nordisk in the U.S.:

Novo Nordisk is a leading global healthcare company that has been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity and rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With U.S. headquarters in New Jersey and commercial, production and research facilities in seven states plus Washington DC, Novo Nordisk employs approximately 8,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.